Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Director/PDMR Shareholding

18 Jul 2016 16:38

RNS Number : 5129E
Motif Bio PLC
18 July 2016
Β 

Motif Bio plc

("Motif Bio" or the "Company")

Β 

Notification and public disclosure of transactions by PDMR and persons closely associated with them

Β 

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 15 July 2016 it was notified that Amphion Innovations plc ("Amphion") had pledged an additional 1,400,000 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility (the "Share Pledge"). In total, Amphion has pledged 16,306,145 ordinary shares in the Company in relation to the Share Pledge. As a result of the Share Pledge, Amphion will transfer legal title to but will retain the beneficial interest in these pledged ordinary shares. Richard Morgan and Robert Bertoldi, non-executive Chairman and executive director of the Company respectively, are also directors of Amphion (the "Amphion Directors"). Amphion is therefore a "Person Closely Associated" with the Amphion Directors under the Market Abuse Regulation.

Β 

The Share Pledge does not change the number of ordinary shares of the Company in issue.

Β 

For further information please contact:

Β 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

Β 

Β 

Β 

Zeus Capital Limited (NOMAD & BROKER)

+44 (0)20 3829 5000

Phil Walker/Giles Balleny

Β 

Dominic Wilson

Β 

Β 

Β 

Northland Capital Partners Limited (BROKER)

+44 (0)203 861 6625

Patrick Claridge/ David Hignell

Β 

John Howes/ Rob Rees (Broking)

Β 

Β 

Β 

Walbrook PR Ltd. (FINANCIAL PR & IR)

+44 (0) 20 7933 8780 or motifbio@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

Mike Wort

Mob: +44 (0)7900 608 002

Β 

Β 

MC Services AG (EUROPEAN IR)

+49 (0)89 210 2280

Raimund Gabriel

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

1

Details of the person discharging managerial responsibilities/person closely associated

Β 

a)

Name

Β 

Amphion Innovations Plc

Β 

2

Reason for the notification

Β 

a)

Position/status

Β 

Person Closely Associated with PDMRs of Motif Bio Plc (Robert Bertoldi and Richard Morgan)

Β 

b)

Initial notification/Amendment

Β 

Initial Notification

Β 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Name

Motif Bio Plc

Β 

b)

LEI

N/A

Β 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Ordinary Shares

Β 

ISIN GB00BVVT4H71

Β 

b)

Nature of the transaction

Β 

Transfer of the legal but not beneficial interest in 1,400,000 Ordinary Shares by way of a pledge for a loan

Β 

Β 

c)

Price(s) and volume(s)

Β 

Β 

Price(s)

Volume(s)

N/A

1,400,000

Β 

d)

Aggregated information

Β 

Price(s)

Volume(s)

N/A

1,400,000

Β 

e)

Date of the transaction

Β 

15 July 2016

Β 

Β 

f)

Place of the transaction

Β 

Β 

N/A

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHEASXPFDPKEFF
Date   Source Headline
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
20th Jul 20157:00 amRNSExercise of Options
17th Jul 20157:00 amRNSFDA QIDP Designation for Iclaprim for HABP
15th Jul 20157:00 amRNSNew Addition to Scientific Advisory Board
10th Jul 20153:29 pmRNSExercise of Options
10th Jul 20151:37 pmRNSResult of General Meeting
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPlacing to raise £22 million and Change of Adviser
9th Jun 20157:00 amRNSAudited Non-Statutory Financial Statements
4th Jun 20154:41 pmRNSSecond Price Monitoring Extn
4th Jun 20154:35 pmRNSPrice Monitoring Extension
1st Jun 20157:00 amRNSMotif partners with Leading Global CRO
28th May 20157:00 amRNSFDA Meeting Minutes Confirming Iclaprim Phase III
12th May 20157:01 amRNSMOTIF SELECTED TO PRESENT AT BIOTECH EVENT
7th May 20157:00 amRNSFunding Strategy Update
15th Apr 20157:01 amRNSFDA Results
15th Apr 20157:00 amRNSFDA agree to enter clinical development programme
2nd Apr 20157:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.